The Concentration of Soluble Extracellular Amyloid-β Protein in Acute Brain Slices from CRND8 Mice

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Waters, Jack ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN SLICE; DIFFUSION; IN VIVO STUDY; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PROTEIN SECRETION; SYNAPSE; TISSUE LEVEL; ANIMAL; BRAIN; DOSE RESPONSE; ELECTROPHYSIOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; NERVE CELL PLASTICITY; STATISTICAL MODEL; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

MUS;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; GENE EXPRESSION REGULATION; MICE; MICE, TRANSGENIC; MODELS, STATISTICAL; NEURONAL PLASTICITY; PEPTIDE FRAGMENTS; SYNAPTIC TRANSMISSION;

EID: 78650844601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015709     Document Type: Article

References (43)

1. Klein WL (2002) ADDLs & protofibrils-the missing links? Neurobiol Aging 23: 231-233.
2. Walsh DM, Selkoe DJ (2007) Aβ Oligomers-a decade of discovery. J Neurochem 101: 1172-1184.
3. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG (2009) Aβ aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 13(3): 412-421.
4. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, et al. (1991) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13: 179-189.
5. Arrigada PA, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 42: 1681-1688.
6. Crystal H, Dickson D, Fuld P, Masur D, Scott R, et al. (1998) Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38: 1682-1687.
7. Katzman R, Terry R, DeTeresa R, Brown T, Davis P, et al. (1988) Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 23: 138-144.
8. Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, et al. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155(3): 853-862.
9. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, et al. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866.
10. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, et al. (2000) Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283(12): 1571-1577.
11. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8(1): 79-84.
12. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, et al. (1999) Plaqueindependent disruption of neural circuits in Alzheimer's disease mouse models. PNAS 96(6): 3228-3233.
13. Larson J, Lynch G, Games D, Seubert P (1999) Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 840(1-2): 23-35.
14. Zaman SH, Parent A, Laskey A, Lee MK, Borchelt DR, et al. (2000) Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol Dis 7: 54-63.
15. Small DH, Mok SS, Bornstein JC (2001) Alzheimer's disease and Aβ toxicity: from top to bottom. Nat Rev Neurosci 2: 595-598.
16. Jolas T, Zhang X-S, Zhang Q, Wong G, Vecchio RD, et al. (2002) Long-term potentiation is increased in the CA1 area of the hippocampus of APPswe/ind CRND8 mice. Neurobiol Dis 11: 394-409.
17. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298: 789-791.
18. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416: 535-539.
19. Wang H-W, Pasternak JF, Kuo H, Ristic H, Lambert MP, et al. (2002) Soluble oligomers of b-amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924: 133-140.
20. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, et al. (2003) APP processing and synaptic function. Neuron 37: 925-937.
21. Stern E, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, et al. (2004) Cortical synaptic integration in vivo is disrupted by amyloid-β plaques. J Neurosci 24(19): 4535-4540.
22. Puzzo D, Privitera L, Leznik E, Fà M, Staniszewski A, et al. (2008) Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28(53): 14537-14545.
23. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine 14(8): 837-842.
24. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid b-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572: 477-492.
25. Tseng BP, Esler WP, Clish CB, Stimson ER, Ghilardi JR, et al. (1999) Deposition of monomeric, not oligomeric, Aβ mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry 38: 10424-10431.
26. Massi F, Peng JW, Lee JP, Straub JE (2001) Simulation study of the structure and dynamics of the Alzheimer's amyloid peptide congener in solution. Biophys J 80: 31-44.
27. Koch C (1999) Biophysics of computation: information processing in single neurons. New York: Oxford UP.
28. Syková E, Nicholson C (2008) Diffusion in brain extracellular space. Physiol Rev 88: 1277-1340.
29. Saxton MJ (2007) Modeling 2D and 3D diffusion. Methods in Molecular Biology 400: 295-321.
30. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 23(26): 8844-8853.
31. Abramowski D, Wiederhold K-H, Furrer U, Jaton A-L, Neuenschwander A, et al. (2008) Dynamics of Aβ turnover and deposition in different β-amyloid precursor protein transgenic mouse models following γ-secretase inhibition. J Pharmacol Exp Therapeutics 327(2): 411-424.
32. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, et al. (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nature Medicine 12(7): 856-861.
33. De Strooper B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90: 465-494.
34. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, et al. (2005) Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48: 913-922.
35. Chishti MA, Yang D-S, Janus C, Phinney AL, Horne P, et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276: 21562-21570.
36. Hyde LA, Kazdoba TM, Grilli M, Lozza G, Brussa R, et al. (2005) Ageprogressing cognitive impairments and neuropathology in transgenic CRND8 mice. Behav Brain Res 160: 344-355.
37. Ambrée O, Touma C, Görtz N, Keyvani K, Paulus W, et al. (2006) Activity changes and marked stereotypic behavior precede Aβ pathology in TgCRND8 Alzheimer mice. Neurobiol Aging 27: 955-964.
38. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, et al. (2010) Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGluR5. Neuron 66: 739-754.
39. Phinney AL, Drisaldi B, Schmidt SD, Lugowski S, Coronado V, et al. (2003) In vivo reduction of amyloid-β by a mutant copper transporter. PNAS 100(24): 14193-14198.
40. Ghersi-Egea J-F, Gorevic PD, Ghiso J, Frangione B, Patlak CS, et al. (1996) Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67: 880-883.
41. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, et al. (2000) Clearance of Alzheimer's amyloid-b1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106: 1489-1499.
42. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, et al. (2002) Plaque-associated disruption of CSF and plasma amyloid-β (Ab) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81: 229-236.
43. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457: 1128-1132.